Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
16 juil. 2024 08h05 HE
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21 mai 2024 08h05 HE
|
Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09 janv. 2024 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
23 août 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with...
Organovo Announces FXR Program
21 mars 2023 08h05 HE
|
Organovo, Inc.
SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated...
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
15 nov. 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using...
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h20 HE
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Announces Postponement of Annual Meeting of Stockholders
06 sept. 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate...
Organovo Achieves 3D Tissue Model for Crohn’s Disease
17 mai 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel...
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
01 mars 2022 08h05 HE
|
Organovo, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for...